BACKGROUND

Cytomegalovirus exists in 50%-80% of the world population in clinically undetected form due to their immunocompetent status. We describe a case of COVID-19 pneumonia on tocolizumab presenting with massive lower gastrointestinal bleeding due to Cytomegalovirus colitis confirmed by histopathology and serology. The performance of life-saving hemicolectomy saved our patient. Cytomegalovirus (CMV) is a double-stranded deoxyribonucleic acid virus belonging to the Herpesviridae family.1 It is more commonly seen in individuals with inflammatory bowel disease (IBD), hematological malignancies, organ transplantation, acquired immunodeficiency syndrome (AIDS), and patients on immunosuppressive therapy.2 The majority of primary CMV infections among immunocompetent people go not discovered.3 Nonspecific fever, occasionally accompanied by pancytopenia, characterizes uncomplicated CMV infection. Ulcerative changes can be seen when the colon becomes compromised by tissue-invasive CMV. Watery diarrhea may begin to develop due to an inflammatory response, which might develop further into profuse bloody diarrhea. Subsequently, the colon may obstruct due to the development of inflammatory polyps. Severe inflammation and vasculitis may lead to perforation and peritonitis of the bowel due to ischemia and transmural necrosis.4 We describe a case of COVID-19 pneumonia on immunosuppressive treatment presenting with life-threatening lower gastrointestinal bleeding due to CMV colitis confirmed by serology and histopathology (Figures 1-4).

Received: 14 August 2020 | Revised: 25 September 2020 | Accepted: 12 October 2020

DOI: 10.1002/ccr3.3487

CASE REPORT

Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19

Mohamad Y. Khatib | Karimulla S. Shaik | Amna A. Ahmed | Mohammad A. Alwraidat | Ahmed S. Mohamed | Mohamad R. Abou Kamar | Mouhammad Z. Sharaf Eldean | Bashar K. Aldaraiseh | Abdulqadir J. Nashwan

1Critical Care Unit, Hazm Mebaireek General Hospital (HMGH), Hamad Medical Corporation (HMC), Doha, Qatar
2Department of Infectious Diseases, Communicable Disease Center (CDC), Hamad Medical Corporation (HMC), Doha, Qatar
3Department of Laboratory Medicine and Pathology (DLMP), Hamad Medical Corporation (HMC), Doha, Qatar

Correspondence
Abdulqadir J. Nashwan, Critical Care Unit, Hazm Mebaireek General Hospital (HMGH), Hamad Medical Corporation (HMC), P.O.Box 3050 Doha, Qatar. Email: anashwan@hamad.qa

Abstract
The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment will prevent life-threatening bleeding and mortality.

KEYWORDS
COVID-19, cytomegalovirus colitis, double-barrel colostomy, lower gastrointestinal bleeding, tocilizumab
2 | CASE REPORT

A 42-year-old male patient with no past medical comorbidities was admitted to our Medical Intensive Care Unit (MICU) with a positive polymerase chain reaction (PCR) test for SARS-CoV-2 performed 7 days prior to admission. His presenting symptoms were fever, shortness of breath, cough, and generalized myalgia. For COVID-19 pneumonia, he was initially supported with noninvasive ventilation (NIV) in a prone position. On day 2 of admission, there was a worsening of chest infiltrates with a spontaneous right pneumothorax for which a chest drain was placed. On the same day, he got intubated and proned for severe adult respiratory distress syndrome (ARDS) with a low Pao2/Fio2 ratio of 107 (Figure 5).

On day 3 of admission, he had a persistent unremitting fever, high ferritin levels (3584 ng/L), and high interleukin-6 levels (176 pg/mL). There was strong suspicion for the presence of cytokine storm; hence, the patient was given an IL-6 inhibitor, Tocilizumab (400mg).

On day 9, he had an upper gastrointestinal bleed (melena) with a drop in hemoglobin (Hb) from 10.5 gm/dl to 9 gm/dl. The gastroenterology team had managed him conservatively with proton pump inhibitors and by withholding low molecular weight heparin (LMWH). The melena subsided and Hb levels were stable. He received the second dose of tocilizumab 400 mg on the 16th day of ICU stay. He had another episode of melena with a significant drop in hemoglobin from 9 to 6 gm/dL on day 22 of admission. Esophagogastroduodenoscopy performed on the same day did not reveal any active bleeder or collection up to D3 of the duodenum. During this time, he was supported with multiple blood transfusions, and intravenous fluids, and the patient was stabilized hemodynamically.

He was tracheostomized due to prolonged intubation on day 28 of ICU stay. On the same day, he developed fresh bleeding per rectum with a drop in hemoglobin from 7.4 to 5.6 gm/dL. He was immediately taken for colonoscopy. The procedure was performed with great difficulty, and the scope could be advanced till the splenic flexure of the colon only. The colon was filled with blood clots, and fresh blood was noted circumferentially. The scope could not be passed further due to poor visibility owing to blood clots. Hemostasis could not be achieved, as no active bleeder was identified.

A computed tomography (CT) angiogram was performed to identify a bleeder and for possible angioembolization. No bleeder could be found, and the only positive finding was mural thickening with intramural axial hemorrhage involving the splenic flexure and proximal part of the descending colon (Figure 6). In view of hemodynamic instability and ongoing bleeding, a multidisciplinary team of surgeons decided to take him for life-saving emergency laparotomy.

On the table, colonoscopy was performed through the enterostomy site and passed the scope up to three meters of the small bowel, no bleeding site was identified, and enterostomy was closed. Left hemicolecotomy was done in view of the suspicious site of bleeding at the splenic flexure, and double-barrel stoma was created. The histopathology of the resected colon was reported as CMV colitis with colonic perforation and serology confirmed the
CMV infection. He was then started on Ganciclovir therapy 220 mg once daily for 4 days, followed by 440mg every 12 hours for 3 weeks. Timely diagnosis and performance of life-saving surgery helped our patient's survival. During the MICU stay, he received hydroxychloroquine, antibiotics, antifungals, and methylprednisolone for COVID-19 ARDS. The patient was successfully discharged to the inpatient ward with a functional colostomy on day 50. On day 61, SARS-CoV-2 PCR was negative, and the patient was discharged to a rehabilitation center.

3 | DISCUSSION

CMV infections are becoming more prevalent in immunocompetent patients. Recently, with the outbreak of COVID-19 disease, many studies have suggested that COVID-19 may activate dysregulated host immune responses, wherein interleukin-6 (IL-6) levels are elevated in cases of severe COVID-19. The role of antihuman interleukin-6 receptor (IL-6R) monoclonal antibody such as tocilizumab may be beneficial. However, the available evidence is still inconclusive of its routine use against COVID-19.
Al-Omari et al noted that the risk factors such as immunocompromised state, mechanical ventilation, and sepsis were found to be strongly associated with CMV. In contrast, the use of corticosteroids, blood transfusion, and stress was weakly associated. They found no association with risk factors such as age, gender, disease severity scores, and active malignancy.

CMV demonstrates an organ-specific tropism within the body, affecting mainly hemopoietic stem cells and parenchymal connective tissue. As per the systemic review done by Rafailidis et al, in immunosuppressed patients with tissue-invasive (TI) CMV, the gastrointestinal tract is the most commonly affected and comprises almost 30% of the disease. CMV lesions may be present throughout the gastrointestinal tract, from the oral cavity to the rectum. However, colon involvement is the most common, comprising up to 94% of cases. For viral reactivation in the immunocompetent individuals, critical illness is a major predisposing factor for developing TI-CMV disease as in our case.

IL-6 has proinflammatory and antiviral properties. With IL-6 antagonist therapy reactivation of CMV, EBV is a potential concern. Other opportunistic infections like candida, Pneumocystis jirovecii pneumonia, Herpes zoster, EBV hepatitis, Tuberculosis, and asymptomatic Mycobacterium avium-intracellulare have been reported in clinical trials. Van duin et al reported a case of CMV reactivation with pneumonitis while being treated with tocilizumab for rheumatoid arthritis. In a patient being treated with tocilizumab for rheumatoid arthritis, acute hepatitis and gastric erosions induced by CMV reactivation were reported by Kamura et al.

The presence of CMV infection in our patient was diagnosed based on the presence of inclusion bodies on histopathology and subsequently confirmed by viral serology. Biopsy with immunohistochemistry using monoclonal antibodies against CMV antigens is now considered the gold standard. The characteristic Owl’s eye inclusion bodies are highly specific for CMV. The human blood-derived products (convalescent plasma, immunoglobulin) and immune-modulatory therapies, like tocilizumab and corticosteroids, studied extensively for the treatment of severe SARS-CoV-2 infection. In the RECOVERY trial, dexamethasone therapy has shown a mortality benefit among COVID 19 patients who were requiring supplemental oxygen. Although the risk associated with steroid therapy is weak, it cannot be completely ruled out in the occurrence of CMV infection.

We suggest high-risk patients receiving tocilizumab should be screened for viral reactivation and other opportunistic infections.

### 4 CONCLUSION

This case highlights the importance of keeping a high suspicion and diagnosing the pathology at the earliest to treat and control the disease in these critically ill patients. Though they may be immunocompetent with no risk factors prior to admission to the ICU, they become vulnerable, and the risk of developing primary/latent CMV infection is high. A timely diagnosis can prevent prolonged ICU and hospital stay. It also warrants judicious use of corticosteroids and other immunomodulatory drugs like tocilizumab in critically ill patients. In the present scenario, while treating patients with COVID-19, the use of immunosuppressive therapy should be justified while being alert for signs and symptoms of CMV reactivation and other opportunistic infections. Early recognition of CMV infection and initiation of early treatment will prevent life-threatening bleeding and mortality.

### ACKNOWLEDGMENTS

We thank the patient for allowing us to share his case. Open-access funding provided by the Qatar National Library. Published with written consent of the patient.

### CONFLICT OF INTEREST

None declared.

### AUTHOR CONTRIBUTIONS

MYK, KSS, AAA, MAA, AJN, ASM: involved in data collection, literature search, and manuscript preparation. MZS and BKA: involved in histopathology slides and manuscript preparation. All authors read and approved the final manuscript.

### ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The article describes a case report. Therefore, no additional permission from our Ethics Committee was required.

### CONSENT FOR PUBLICATION

The consent for publication was obtained.

### DATA AVAILABILITY STATEMENT

All data generated or analyzed during this study are included in this published article.

### ORCID

Ahmed S. Mohamed https://orcid.org/0000-0002-2107-5357
Abdulqadir J. Nashwan https://orcid.org/0000-0003-4845-4119
REFERENCES

1. Zhang LJ, Haniff P, Rutherford C, Churchill W, Crumpacker CS. Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood. *J Infect Dis.* 1995;171(4):1002-1006.

2. Nakase H, Herfarth H. Cytomegalovirus colitis, cytomegalovirus hepatitis and systemic cytomegalovirus infection: common features and differences. *Inflamm Intest Dis.* 2016;1(1):15-23.

3. Rawlinson W, Scott G. Cytomegalovirus: a common virus causing serious disease. *Aust Fam Physician.* 2003;32(10):789.

4. Kram HB, Shoemaker WC. Intestinal perforation due to cytomegalovirus infection in patients with AIDS. *Dis Colon Rectum.* 1990;33(12):1037-1040.

5. Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. *Virol J.* 2008;5(1):1-13.

6. Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta-analysis. *MedRxiv.* 2020.

7. Al-Omari A, Ajlamma F, Alhazzani W, Salih S, Arabi Y. Cytomegalovirus infection in immunocompetent critically ill adults: literature review. *Ann Intens Care.* 2016;6(1):110.

8. Fakhreddine AY, Frenette CT, Konijeti GG. A practical review of cytomegalovirus in gastroenterology and hepatology. *Gastroenterol Res Pract.* 2019;2019:1-11.

9. Jacob S, Zayyani NR. Cytomegalovirus colitis masquerading as rectal malignancy in an immunocompetent patient. *Indian J Pathol Microbiol.* 2015;58(1):80.

10. Lee C-Y, Chen Y-H, Lu P-L. Reactivated cytomegalovirus proctitis in an immunocompetent patient presenting as nosocomial diarrhea: a case report and literature review. *BMC Infect Dis.* 2017;17(1):113.

11. Osawa R, Singh N. Cytomegalovirus infection in critically ill patients: a systematic review. *Crit Care.* 2009;13(3):R68.

12. van Duin D, Miranda C, Husni E. Cytomegalovirus viremia, pneumonitis, and tocilizumab therapy. *Emerg Infect Dis.* 2011;17(4):754.

13. Komura T, Ohta H, Nakai R, et al. Cytomegalovirus reactivation induced acute hepatitis and gastric erosions in a patient with rheumatoid arthritis under treatment with an anti-IL-6 receptor antibody, tocilizumab. *Intern Med.* 2016;55(14):1923-1927.

14. Niv E, Ovadia B, Groisman G, Kopelman Y. CMV-Induced Severe Colonic Stricture in an Adult Crohn’s Disease Patient. *Dig Dis Sci.* 2020;1-4.

15. Malik A, Vaze R, Buckshaw R, Nellis E, Shah HA. Case of CMV Colitis Seen in DRESS: 1571. American Journal of Gastroenterology. 2019;114(2019 ACG Annual Meeting Abstracts):S875-S876.

16. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19-Preliminary Report. *N Engl J Med.* 2020;1-11.

How to cite this article: Khatib MY, Shaik KS, Ahmed AA, et al. Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19. *Clin Case Rep.* 2021;9:148–152. [https://doi.org/10.1002/ccr3.3487](https://doi.org/10.1002/ccr3.3487)